- Home
- CBZ vs MLYS Comparison
CBZ vs MLYS Comparison
Compare CBZ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | MLYS |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CBZ | MLYS |
|---|---|---|
| Price | $54.39 | $33.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 502.5K | ★ 1.5M |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,675,607,000.00 | N/A |
| Revenue This Year | $55.67 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $32.02 | ★ N/A |
| Revenue Growth | ★ 59.19 | N/A |
| 52 Week Low | $47.89 | $8.24 |
| 52 Week High | $90.13 | $47.65 |
Technical Indicators
Market Signals| Indicator | CBZ | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 29.64 |
| Support Level | $52.46 | $34.21 |
| Resistance Level | $54.42 | $37.70 |
| Average True Range (ATR) | 1.59 | 1.56 |
| MACD | 0.19 | -0.13 |
| Stochastic Oscillator | 93.65 | 14.42 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.